Literature DB >> 16275947

Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63.

K H Chan1, V C C Cheng, P C Y Woo, S K P Lau, L L M Poon, Y Guan, W H Seto, K Y Yuen, J S M Peiris.   

Abstract

The serological response profile of severe acute respiratory syndrome (SARS) coronavirus (CoV) infection was defined by neutralization tests and subclass-specific immunofluorescent (IF) tests using serial sera from 20 patients. SARS CoV total immunoglobulin (Ig) (IgG, IgA, and IgM [IgGAM]) was the first antibody to be detectable. There was no difference in time to seroconversion between the patients who survived (n = 14) and those who died (n = 6). Although SARS CoV IgM was still detectable by IF tests with 8 of 11 patients at 7 months postinfection, the geometric mean titers dropped from 282 at 1 month postinfection to 19 at 7 months (P = 0.001). In contrast, neutralizing antibody and SARS CoV IgGAM and IgG antibody titers remained stable over this period. The SARS CoV antibody response was sometimes associated with an increase in preexisting IF IgG antibody titers for human coronaviruses OC43, 229E, and NL63. There was no change in IF IgG titer for virus capsid antigen from the herpesvirus that was used as an unrelated control, Epstein-Barr virus. In contrast, patients who had OC43 infections, and probably also 229E infections, without prior exposure to SARS CoV had increases of antibodies specific for the infecting virus but not for SARS CoV. There is a need for awareness of cross-reactive antibody responses between coronaviruses when interpreting IF serology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275947      PMCID: PMC1287763          DOI: 10.1128/CDLI.12.11.1317-1321.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  19 in total

1.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

Authors:  Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

2.  Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia.

Authors:  Patrick C Y Woo; Susanna K P Lau; Chung-ming Chu; Kwok-hung Chan; Hoi-wah Tsoi; Yi Huang; Beatrice H L Wong; Rosana W S Poon; James J Cai; Wei-kwang Luk; Leo L M Poon; Samson S Y Wong; Yi Guan; J S Malik Peiris; Kwok-yung Yuen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Epstein-Barr virus (EBV) infection in infancy.

Authors:  K H Chan; J S Tam; J S Peiris; W H Seto; M H Ng
Journal:  J Clin Virol       Date:  2001-04       Impact factor: 3.168

4.  False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide.

Authors:  Patrick C Y Woo; Susanna K P Lau; Beatrice H L Wong; Kwok-Hung Chan; Wai-Ting Hui; Grace S W Kwan; J S Malik Peiris; Robert B Couch; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

5.  A novel coronavirus associated with severe acute respiratory syndrome.

Authors:  Thomas G Ksiazek; Dean Erdman; Cynthia S Goldsmith; Sherif R Zaki; Teresa Peret; Shannon Emery; Suxiang Tong; Carlo Urbani; James A Comer; Wilina Lim; Pierre E Rollin; Scott F Dowell; Ai-Ee Ling; Charles D Humphrey; Wun-Ju Shieh; Jeannette Guarner; Christopher D Paddock; Paul Rota; Barry Fields; Joseph DeRisi; Jyh-Yuan Yang; Nancy Cox; James M Hughes; James W LeDuc; William J Bellini; Larry J Anderson
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

Review 6.  The aetiology, origins, and diagnosis of severe acute respiratory syndrome.

Authors:  L L M Poon; Y Guan; J M Nicholls; K Y Yuen; J S M Peiris
Journal:  Lancet Infect Dis       Date:  2004-11       Impact factor: 25.071

7.  Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.

Authors:  Xiao-Yan Che; Li-Wen Qiu; Zhi-Yong Liao; Ya-di Wang; Kun Wen; Yu-Xian Pan; Wei Hao; Ya-Bo Mei; Vincent C C Cheng; Kwok-Yung Yuen
Journal:  J Infect Dis       Date:  2005-05-06       Impact factor: 5.226

8.  Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan.

Authors:  Po-Ren Hsueh; Cheng-Hsiang Hsiao; Shiou-Hwei Yeh; Wei-Kung Wang; Pei-Jer Chen; Jin-Town Wang; Shan-Chwen Chang; Chuan-Liang Kao; Pan-Chyr Yang
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

9.  Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage.

Authors:  Eric J Snijder; Peter J Bredenbeek; Jessika C Dobbe; Volker Thiel; John Ziebuhr; Leo L M Poon; Yi Guan; Mikhail Rozanov; Willy J M Spaan; Alexander E Gorbalenya
Journal:  J Mol Biol       Date:  2003-08-29       Impact factor: 5.469

10.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.

Authors:  J S M Peiris; C M Chu; V C C Cheng; K S Chan; I F N Hung; L L M Poon; K I Law; B S F Tang; T Y W Hon; C S Chan; K H Chan; J S C Ng; B J Zheng; W L Ng; R W M Lai; Y Guan; K Y Yuen
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

View more
  56 in total

Review 1.  Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns.

Authors:  Nicole Baumgarth; Janko Nikolich-Žugich; F Eun-Hyung Lee; Deepta Bhattacharya
Journal:  J Immunol       Date:  2020-09-04       Impact factor: 5.422

2.  Naturally occurring anti-Escherichia coli protein antibodies in the sera of healthy humans cause analytical interference in a recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay for serodiagnosis of severe acute respiratory syndrome.

Authors:  Chi Wai Yip; Chung Chau Hon; Fanya Zeng; Ken Y C Chow; Kwok Hung Chan; Joseph S M Peiris; Frederick C C Leung
Journal:  Clin Vaccine Immunol       Date:  2006-11-15

3.  Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method.

Authors:  E R Gaunt; A Hardie; E C J Claas; P Simmonds; K E Templeton
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

4.  An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus.

Authors:  David M Patrick; Martin Petric; Danuta M Skowronski; Roland Guasparini; Timothy F Booth; Mel Krajden; Patrick McGeer; Nathalie Bastien; Larry Gustafson; Janet Dubord; Diane Macdonald; Samara T David; Leila F Srour; Robert Parker; Anton Andonov; Judith Isaac-Renton; Nadine Loewen; Gail McNabb; Alan McNabb; Swee-Han Goh; Scott Henwick; Caroline Astell; Jian Ping Guo; Michael Drebot; Raymond Tellier; Francis Plummer; Robert C Brunham
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-11       Impact factor: 2.471

5.  Crystallization and preliminary X-ray diffraction analysis of the N-terminal domain of human coronavirus OC43 nucleocapsid protein.

Authors:  I Jung Chen; Chia Cheng Chou; Chia Ling Liu; Cheng Chung Lee; Lou Sing Kan; Ming Hon Hou
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-06-24

6.  Understanding Human Coronavirus HCoV-NL63.

Authors:  Sahar Abdul-Rasool; Burtram C Fielding
Journal:  Open Virol J       Date:  2010-05-25

7.  Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.

Authors:  Anastasia N Vlasova; Xinsheng Zhang; Mustafa Hasoksuz; Hadya S Nagesha; Lia M Haynes; Ying Fang; Shan Lu; Linda J Saif
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

8.  Use of antibody avidity assays for diagnosis of severe acute respiratory syndrome coronavirus infection.

Authors:  K H Chan; K Sonnenberg; M Niedrig; S Y Lam; C M Pang; K M Chan; S K Ma; W H Seto; J S M Peiris
Journal:  Clin Vaccine Immunol       Date:  2007-09-19

9.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

Authors:  Ann M Arvin; Katja Fink; Michael A Schmid; Andrea Cathcart; Roberto Spreafico; Colin Havenar-Daughton; Antonio Lanzavecchia; Davide Corti; Herbert W Virgin
Journal:  Nature       Date:  2020-07-13       Impact factor: 49.962

10.  Elucidation of the stability and functional regions of the human coronavirus OC43 nucleocapsid protein.

Authors:  Chun-Yu Huang; Yen-Lan Hsu; Wan-Ling Chiang; Ming-Hon Hou
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.